Insider Selling: Alphatec (NASDAQ:ATEC) General Counsel Sells 22,889 Shares of Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) General Counsel Tyson Eliot Marshall sold 22,889 shares of the stock in a transaction on Friday, December 5th. The stock was sold at an average price of $21.47, for a total value of $491,426.83. Following the completion of the transaction, the general counsel directly owned 345,442 shares of the company’s stock, valued at approximately $7,416,639.74. The trade was a 6.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Tyson Eliot Marshall also recently made the following trade(s):

• On Thursday, November 20th, Tyson Eliot Marshall sold 70,000 shares of Alphatec stock. The stock was sold at an average price of $19.51, for a total transaction of $1,365,700.00.

Alphatec Trading Down 1.4%

ATEC traded down $0.29 during trading on Tuesday, reaching $20.67. The company had a trading volume of 1,429,220 shares, compared to its average volume of 2,120,693. The firm’s 50-day simple moving average is $17.92 and its 200 day simple moving average is $14.90. The company has a market cap of $3.07 billion, a price-to-earnings ratio of -19.88 and a beta of 1.08. Alphatec Holdings, Inc. has a 12-month low of $8.69 and a 12-month high of $22.66. The company has a debt-to-equity ratio of 43.02, a quick ratio of 1.24 and a current ratio of 1.99.

Alphatec (NASDAQ:ATEC) last issued its earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.09. The company had revenue of $196.50 million for the quarter, compared to analyst estimates of $182.78 million. During the same period last year, the business earned ($0.28) EPS. The company’s quarterly revenue was up 30.4% on a year-over-year basis. Equities research analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on ATEC shares. Piper Sandler restated an “overweight” rating and issued a $25.00 price objective (up previously from $20.00) on shares of Alphatec in a research note on Friday, October 31st. HC Wainwright raised their price target on Alphatec from $20.00 to $24.00 and gave the company a “buy” rating in a report on Friday, October 31st. Wells Fargo & Company boosted their price target on shares of Alphatec from $14.00 to $16.00 and gave the company an “overweight” rating in a report on Thursday, October 16th. Canaccord Genuity Group increased their price objective on Alphatec from $20.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Finally, Needham & Company LLC lifted their target price on Alphatec from $16.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $22.20.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Aster Capital Management DIFC Ltd bought a new stake in Alphatec during the 3rd quarter valued at approximately $34,000. Osterweis Capital Management Inc. bought a new position in shares of Alphatec in the second quarter worth approximately $37,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Alphatec during the third quarter valued at approximately $73,000. Nisa Investment Advisors LLC raised its stake in shares of Alphatec by 22.4% in the second quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock worth $63,000 after purchasing an additional 1,045 shares during the last quarter. Finally, State of Alaska Department of Revenue bought a new position in Alphatec during the 3rd quarter valued at about $120,000. Hedge funds and other institutional investors own 66.35% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.